Treatment with the anti-tumour necrosis factor alpha monoclonal antibody infliximab has been shown to be effective in moderate-to-severe ulcerative colitis. However, its effect on the mucosal histopathological abnormalities of this disease is largely unknown. This study aimed to assess the immunohistological effect of infliximab in ulcerative colitis.

Hassan, C., Ierardi, E., Burattini, O., De Francesco, V., Zullo, A., Stoppino, G., Panella, C., Morini, S., Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab, <<DIGESTIVE AND LIVER DISEASE>>, N/A; 39 (9): 811-817. [doi:10.1016/j.dld.2007.06.003] [http://hdl.handle.net/10807/34853]

Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab

Hassan, Cesare;
2007

Abstract

Treatment with the anti-tumour necrosis factor alpha monoclonal antibody infliximab has been shown to be effective in moderate-to-severe ulcerative colitis. However, its effect on the mucosal histopathological abnormalities of this disease is largely unknown. This study aimed to assess the immunohistological effect of infliximab in ulcerative colitis.
2007
Inglese
Hassan, C., Ierardi, E., Burattini, O., De Francesco, V., Zullo, A., Stoppino, G., Panella, C., Morini, S., Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab, <<DIGESTIVE AND LIVER DISEASE>>, N/A; 39 (9): 811-817. [doi:10.1016/j.dld.2007.06.003] [http://hdl.handle.net/10807/34853]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/34853
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact